OBJECTIVE: To determine whether controlling for differences in the use of invasive therapy affects racial/ethnic differences in survival of early-stage hepatocellular carcinoma (HCC). DESIGN: A retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) HCC data. Invasive therapy was defined as tumor ablation, hepatectomy, or liver transplant. Race/ethnicity was defined as white, black, Asian, Hispanic, or other. Racial/ethnic differences in overall and treatment-adjusted survival were assessed using the Kaplan-Meier method and base- and treatment-stratified multivariable Cox proportional hazards models. PATIENTS: All patients diagnosed as having stage I or II HCC from January 1, 1995, through December 31, 2006 (N = 13 244). SETTING: Data were obtained from the National Cancer Institute's SEER registry. MAIN OUTCOME MEASURES: Differences in survival by race/ethnicity accounting for the use of invasive therapy and treatment benefit. RESULTS: Overall, 32.8% of patients received invasive therapy. We found higher mortality rates in the base survival model for black (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.15-1.33) and Hispanic (1.08; 1.01-1.15) patients and lower mortality rates in Asian patients (0.87; 0.82-0.93) compared with whites. After treatment stratification, compared with white patients, blacks had a 12% higher mortality rate (HR, 1.11; 95% CI, 1.03-1.20), Hispanics had a similar mortality rate (0.97; 0.91-1.04), and Asians had a 16% lower mortality rate (0.84; 0.79-0.89). CONCLUSIONS: For early-stage HCC, racial/ethnic disparities in survival between minority and white patients are notable. After accounting for differences in stage, use of invasive therapy, and treatment benefit, no racial/ethnic survival disparity is evident between Hispanics and whites, but blacks have persistently poor survival.
OBJECTIVE: To determine whether controlling for differences in the use of invasive therapy affects racial/ethnic differences in survival of early-stage hepatocellular carcinoma (HCC). DESIGN: A retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) HCC data. Invasive therapy was defined as tumor ablation, hepatectomy, or liver transplant. Race/ethnicity was defined as white, black, Asian, Hispanic, or other. Racial/ethnic differences in overall and treatment-adjusted survival were assessed using the Kaplan-Meier method and base- and treatment-stratified multivariable Cox proportional hazards models. PATIENTS: All patients diagnosed as having stage I or II HCC from January 1, 1995, through December 31, 2006 (N = 13 244). SETTING: Data were obtained from the National Cancer Institute's SEER registry. MAIN OUTCOME MEASURES: Differences in survival by race/ethnicity accounting for the use of invasive therapy and treatment benefit. RESULTS: Overall, 32.8% of patients received invasive therapy. We found higher mortality rates in the base survival model for black (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.15-1.33) and Hispanic (1.08; 1.01-1.15) patients and lower mortality rates in Asian patients (0.87; 0.82-0.93) compared with whites. After treatment stratification, compared with white patients, blacks had a 12% higher mortality rate (HR, 1.11; 95% CI, 1.03-1.20), Hispanics had a similar mortality rate (0.97; 0.91-1.04), and Asians had a 16% lower mortality rate (0.84; 0.79-0.89). CONCLUSIONS: For early-stage HCC, racial/ethnic disparities in survival between minority and white patients are notable. After accounting for differences in stage, use of invasive therapy, and treatment benefit, no racial/ethnic survival disparity is evident between Hispanics and whites, but blacks have persistently poor survival.
Authors: Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-05-31 Impact factor: 11.382
Authors: Alexis P Chidi; Cindy L Bryce; Larissa Myaskovsky; Michael J Fine; David A Geller; Douglas P Landsittel; Allan Tsung Journal: Ann Surg Date: 2016-02 Impact factor: 12.969
Authors: Richard J Cassidy; Jeffrey M Switchenko; Mark W El-Deiry; Ryan H Belcher; Jim Zhong; Conor E Steuer; Nabil F Saba; Mark W McDonald; David S Yu; Theresa W Gillespie; Jonathan J Beitler Journal: Laryngoscope Date: 2018-09-08 Impact factor: 3.325
Authors: Edith Y Ho; Myrna L Cozen; Hui Shen; Robert Lerrigo; Erica Trimble; James C Ryan; Carlos U Corvera; Alexander Monto Journal: HPB (Oxford) Date: 2014-01-28 Impact factor: 3.647
Authors: Adil H Haider; Valerie K Scott; Karim A Rehman; Catherine Velopulos; Jessica M Bentley; Edward E Cornwell; Waddah Al-Refaie Journal: J Am Coll Surg Date: 2013-01-11 Impact factor: 6.113